155 related articles for article (PubMed ID: 12181422)
21. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine.
Nair RV; Cao W; Morris RE
Immunol Lett; 1995 Dec; 48(2):77-80. PubMed ID: 8719103
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine.
Nair RV; Cao W; Morris RE
Immunol Lett; 1995 Sep; 47(3):171-4. PubMed ID: 8747714
[TBL] [Abstract][Full Text] [Related]
23. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
Rückemann K; Fairbanks LD; Carrey EA; Hawrylowicz CM; Richards DF; Kirschbaum B; Simmonds HA
J Biol Chem; 1998 Aug; 273(34):21682-91. PubMed ID: 9705303
[TBL] [Abstract][Full Text] [Related]
24. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
[TBL] [Abstract][Full Text] [Related]
25. Sex hormones modulate the effects of Leflunomide on cytokine production by cultures of differentiated monocyte/macrophages and synovial macrophages from rheumatoid arthritis patients.
Cutolo M; Montagna P; Brizzolara R; Sulli A; Seriolo B; Villaggio B; Triolo P; Clerico P; Soldano S
J Autoimmun; 2009; 32(3-4):254-60. PubMed ID: 19324522
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
Li Y; Yi L; Cheng S; Wang Y; Wang J; Sun J; Zhang Q; Xu X
J Gen Virol; 2021 Mar; 102(3):. PubMed ID: 33416466
[TBL] [Abstract][Full Text] [Related]
27. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.
Mattar T; Kochhar K; Bartlett R; Bremer EG; Finnegan A
FEBS Lett; 1993 Nov; 334(2):161-4. PubMed ID: 8224241
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.
Xu X; Shen J; Mall JW; Myers JA; Huang W; Blinder L; Saclarides TJ; Williams JW; Chong AS
Biochem Pharmacol; 1999 Nov; 58(9):1405-13. PubMed ID: 10513984
[TBL] [Abstract][Full Text] [Related]
30. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
Sawamukai N; Saito K; Yamaoka K; Nakayamada S; Ra C; Tanaka Y
J Immunol; 2007 Nov; 179(10):6479-84. PubMed ID: 17982036
[TBL] [Abstract][Full Text] [Related]
31. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.
Bruneau JM; Yea CM; Spinella-Jaegle S; Fudali C; Woodward K; Robson PA; Sautès C; Westwood R; Kuo EA; Williamson RA; Ruuth E
Biochem J; 1998 Dec; 336 ( Pt 2)(Pt 2):299-303. PubMed ID: 9820804
[TBL] [Abstract][Full Text] [Related]
32. Two activities of the immunosuppressive metabolite of leflunomide, A77 1726. Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation.
Xu X; Williams JW; Gong H; Finnegan A; Chong AS
Biochem Pharmacol; 1996 Aug; 52(4):527-34. PubMed ID: 8759024
[TBL] [Abstract][Full Text] [Related]
33. Effects of pyrimidine antagonists on sialic acid regeneration in HL-60 cells.
Hindenburg AA; Taub RN; Grant S; Chang G; Baker MA
Cancer Res; 1985 Jul; 45(7):3048-52. PubMed ID: 3859365
[TBL] [Abstract][Full Text] [Related]
34. CAD, A Multienzymatic Protein at the Head of de Novo Pyrimidine Biosynthesis.
Del Caño-Ochoa F; Moreno-Morcillo M; Ramón-Maiques S
Subcell Biochem; 2019; 93():505-538. PubMed ID: 31939163
[TBL] [Abstract][Full Text] [Related]
35. In situ regulation of mammalian CTP synthetase by allosteric inhibition.
Aronow B; Ullman B
J Biol Chem; 1987 Apr; 262(11):5106-12. PubMed ID: 2435724
[TBL] [Abstract][Full Text] [Related]
36. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Breedveld FC; Dayer JM
Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058
[TBL] [Abstract][Full Text] [Related]
37. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.
Kobayashi Y; Ueyama S; Arai Y; Yoshida Y; Kaneda T; Sato T; Shin K; Kumegawa M; Hakeda Y
J Bone Miner Metab; 2004; 22(4):318-28. PubMed ID: 15221489
[TBL] [Abstract][Full Text] [Related]
38. Control of pyrimidine biosynthesis in "Pseudomonas alkanolytica" ATCC 21034.
West TP
J Basic Microbiol; 2004; 44(3):253-7. PubMed ID: 15162399
[TBL] [Abstract][Full Text] [Related]
39. Evidence for transformation-related increase in CTP synthetase activity in situ in human lymphoblastic leukemia.
van den Berg AA; van Lenthe H; Busch S; de Korte D; Roos D; van Kuilenburg AB; van Gennip AH
Eur J Biochem; 1993 Aug; 216(1):161-7. PubMed ID: 8365402
[TBL] [Abstract][Full Text] [Related]
40. Synergistic inhibition of Escherichia coli aspartate transcarbamylase by CTP and UTP: binding studies using continuous-flow dialysis.
England P; Hervé G
Biochemistry; 1992 Oct; 31(40):9725-32. PubMed ID: 1390749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
